Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia

During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Palomba, Emanuele, Carrabba, Maria, Zuglian, Gianluca, Alagna, Laura, Saltini, Paola, Fortina, Valeria, Hu, Cinzia, Bandera, Alessandra, Fabio, Giovanna, Gori, Andrea, Muscatello, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317455/
https://www.ncbi.nlm.nih.gov/pubmed/34332085
http://dx.doi.org/10.1016/j.ijid.2021.07.064
Descripción
Sumario:During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.

Ejemplares similares